Physician profile
Angela E Meadows
NPI 1114975356
$13,863.29
in general payments reported to CMS, 2019-2025
44 companies · $1,956 in 2025
The $1,956 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $1,560 · 2021: $2,161 · 2022: $1,965 · 2023: $2,133 · 2024: $2,055 · 2025: $1,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,112 · Education: $31.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,112.41 |
| Education | $31.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,056.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,481.47 | 2021-2025 | |
| Lilly USA, LLC | $1,392.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,158.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $913.32 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $777.24 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $744.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.59 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.31 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $338.45 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $304.53 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $276.68 | 2022-2025 | |
| Amarin Pharma, INC. | $276.51 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $272.12 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $262.99 | 2019-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $253.86 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Xeris Pharmaceuticals, INC. | $236.42 | 2021-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $202.10 | 2024-2025 | Voquezna |
| Amgen INC. | $169.54 | 2019-2024 | Repatha, Otezla, Evenity |
| Allergan, INC. | $166.36 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $165.19 | 2023-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.86 | 2025 | Caplyta |
| Dexcom, INC. | $148.87 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $127.46 | 2021-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $98.54 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $90.33 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $75.91 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $67.73 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $66.97 | 2019-2023 | |
| Radius Health, INC. | $63.53 | 2019-2020 | |
| Lundbeck LLC | $58.77 | 2021-2023 | Vyepti |
| Verona Pharma, INC. | $54.20 | 2025 | Ohtuvayre |
| Currax Pharmaceuticals LLC | $47.41 | 2020-2023 | Nexletol |
| Sunovion Pharmaceuticals INC. | $46.03 | 2022 | |
| Eisai INC. | $45.98 | 2019-2021 | |
| Grifols USA, LLC | $43.12 | 2019-2023 | Prolastin-C Liquid |
| Astellas Pharma US INC | $37.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.81 | 2022 | |
| Horizon Therapeutics Plc | $24.92 | 2021 | |
| Kyowa Kirin, INC. | $22.09 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $17.02 | 2019 | |
| Insulet Corporation | $14.46 | 2024 | Omnipod |
| Exact Sciences Corporation | $14.40 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $14.15 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.